Clinical Trials | December 04, 2025
Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The company is excluding data from the affected sites to maintain the study's integrity
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Subscribe To Our Newsletter & Stay Updated
